Citations

Clear

4847 citation(s) found for "Yu, Eric".

Reviving the medical lecture: practical tips for delivering effective lectures–an infographic
Gupta, Rajnish K. , Schwenk, Eric S. , Harbell, Monica, Schwenk, Eric S , Gupta, Rajnish K , Harbell, Monica W.

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 22, 2022 | Volume: 47 | Issue: 5 | Pages: 342-342

10.1136/rapm-2022-103540 | PMID 35193969 Get It

Social risk factors predicting outcomes of cervical myelopathy surgery
Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Park, Paul , Alvi, Mohammed Ali , Alvi, Mohammed Ali , Rethorn, Zachary D., Cook, Chad E., Park, Christine, Somers, Tamara, Mummaneni, Praveen V., Chan, Andrew K., Pennicooke, Brenton H., Bisson, Erica F., Asher, Anthony L., Buchholz, Avery L., Bydon, Mohamad, Alvi, Mohammed Ali, Coric, Domagoj, Foley, Kevin T., Fu, Kai-Ming, Knightly, John J., Meyer, Scott, Park, Paul, Potts, Eric A., Shaffrey, Christopher I., Shaffrey, Mark, Than, Khoi D., Tumialan, Luis, Turner, Jay D., Upadhyaya, Cheerag D., Wang, Michael Y., Gottfried, Oren, Turner, Jay D.

Mayo Clinic

Journal of Neurosurgery: Spine | February 18, 2022 | Volume: 37 | Issue: 1 | Pages: 41-48

10.3171/2021.12.spine21874 | PMID 35090132 Get It

OBJECTIVE Combinations of certain social risk factors of race, sex, education, socioeconomic status (SES), insurance, education, employment, and one’s housing situation have been associated with poorer pain and disability outcomes after lumbar spine surgery. To date, an exploration of such factors in patients with cervical spine surgery has not been conducted. The objective of the current work was to 1) define the social risk phenotypes of individuals who have undergone cervical spine surgery for myelopathy and 2) analyze their predictive capacity toward disability, pain, quality of life, and patient satisfaction–based outcomes. METHODS The Cervical Myelopathy Quality Outcomes Database was queried for the period from January 2016 to December 2018. Race/ethnicity, educational attainment, SES, insurance payer, and employment status were modeled into unique social phenotypes using latent class analyses. Proportions of social groups were analyzed for demonstrating a minimal clinically important difference (MCID) of 30% from baseline for disability, neck and arm pain, quality of life, and patient satisfaction at the 3-month and 1-year follow-ups. RESULTS A total of 730 individuals who had undergone cervical myelopathy surgery were included in the final cohort. Latent class analysis identified 2 subgroups: 1) high risk (non-White race and ethnicity, lower educational attainment, not working, poor insurance, and predominantly lower SES), n = 268, 36.7% (class 1); and 2) low risk (White, employed with good insurance, and higher education and SES), n = 462, 63.3% (class 2). For both 3-month and 1-year outcomes, the high-risk group (class 1) had decreased odds (all p < 0.05) of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Being in the low-risk group (class 2) resulted in an increased odds of attaining an MCID score in disability, neck/arm pain, and health-related quality of life. Neither group had increased or decreased odds of being satisfied with surgery. CONCLUSIONS Although 2 groups underwent similar surgical approaches, the social phenotype involving non-White race/ethnicity, poor insurance, lower SES, and poor employment did not meet MCIDs for a variety of outcome measures. This finding should prompt surgeons to proactively incorporate socially conscience care pathways within healthcare systems, as well as to optimize community-based resources to improve outcomes and personalize care for populations at social risk.
In Vivo reflectance confocal microscopy of cutaneous acute graft‐versus‐host disease: concordance with histopathology and interobserver reproducibility of a glossary with representative images
Saknīte, Inga , Gill, Melissa , Alessi‐Fox, Christi , Zwerner, Jeffrey P., Lehman, Julia S. , Shinohara, Michi M. , Chen, H , Byrne, Michael , González, Salvador , Ardigò, Marco , Tkaczyk, Eric R. , Saknite, I , Gill, M , Alessi-Fox, C , Shinohara, M M , Byrne, M , Gonzalez, S , Ardigo, M , Tkaczyk, E R , Lehman, Julia S , Novoa, Roberto A.

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | February 17, 2022 | Volume: 36 | Issue: 7 | Pages: 1034-1044

10.1111/jdv.18004 | PMID 35175678 Get It

AbstractBackgroundThe reliability to non‐invasively identify features of inflammatory dermatoses by reflectance confocal microscopy (RCM) remains unknown. Lack of formal training among RCM readers can result in inconsistent assessments, limiting clinical utility. Specific consensus terminology with representative images is necessary to ensure consistent feature‐level interpretation among RCM readers.Objectives(1) Develop a glossary with representative images of RCM features of cutaneous acute graft‐versus‐host disease (aGVHD) for consistent interpretation among observers, (2) assess the interobserver reproducibility among RCM readers using the glossary, and (3) determine the concordance between RCM and histopathology for aGVHD features.MethodsThrough an iterative process of refinement and discussion among five international RCM experts, we developed a glossary with representative images of RCM features of aGVHD. From April to November 2018, patients suspected of aGVHD were imaged with RCM and subsequently biopsied. 17 lesions from 12 patients had clinically and pathologically confirmed cutaneous aGVHD. For each of these lesions, four dermatopathologists and four RCM readers independently evaluated the presence of aGVHD features in scanned histopathology slides and 1.5 × 1.5 mm RCM submosaics at 4 depths (blockstacks) respectively. RCM cases were adjudicated by a fifth RCM expert. Interobserver reproducibility was calculated by mean pairwise difference (U statistic). Concordance between modalities was determined by fraction of assignments with agreement.ResultsWe present a glossary with representative images of 18 aGVHD features by RCM. The average interobserver reproducibility among RCM readers (75%, confidence interval, CI: 71–79%) did not differ significantly from dermatopathologists (80%, 76–85%). The concordance between RCM and histopathology was 59%.ConclusionsBy using the glossary, the interobserver reproducibility among RCM readers was similar to the interobserver reproducibility among dermatopathologists. There was reasonable concordance between RCM and histopathology to visualize aGVHD features. The implementation of RCM can now be advanced in a variety of inflammatory conditions with a validated glossary and representative image set.
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants
Lowry, Kathryn P. , Geuzinge, H. Amarens , Stout, Natasha K. , Alagöz, Oğuzhan , Hampton, John M. , Koning, Harry J. de , Miglioretti, Diana L. , Ravesteyn, Nicolien T. van , Sprague, Brian L. , Tosteson, Anna N.A. , Weaver, Donald L. , Yaffe, Martin J. , Mandelblatt, Jeanne S. , Kurian, Allison W. , Auer, Paul L. , Berstein, Leslie, Carter, Brian D., Gaudet, Mia M. , Haiman, Christopher, Jacobs, Eric J. , John, Esther M. , Lindström, Sara , Martínez, Elena, Patel, Alpa V. , Reid, Sonya , Taylor, Jack A. , Teras, Lauren R., Vachon, Celine M. , Yao, Song, Ziogas, Argyrios, Goldgar, David E. , Chen, Chen , Chen, C , Miglioretti, Diana L , John, Esther M , Taylor, Jack A , de Koning, Harry J , Kurian, Allison W , Kerlikowske, Karla , Schechter, Clyde B. , Trentham‐Dietz, Amy , Yeh, Jennifer M. , Couch, Fergus J. , Hu, Chunling , Kraft, Peter , Polley, Eric C. , Robson, Mark E. , Hart, Steven N. , Nathanson, Katherine L. , Domchek, Susan M. , Ambrosone, Christine B. , Anton‐Culver, Hoda , Bandera, Elisa V. , Bertrand, Kimberly A. , Burnside, Elizabeth S. , Eliassen, A. Heather , Hodge, James M. , Hunter, David J. , Kooperberg, Charles , Lacey, James V. , Marchand, Loı̈c Le , Ma, Huiyan , Neuhausen, Susan L. , Newcomb, Polly A. , O’Brien, Katie M. , Olson, Janet E. , Ong, Irene M. , Pal, Tuya , Palmer, Julie R. , Rosenberg, Lynn A. , Sandler, Dale P. , Tamimi, Rulla M. , Teras, Lauren R. , Vachon, Celine M. , Weinberg, Clarice R. , Yadav, Siddhartha , Yao, Song , Weitzel, Jeffrey N.

Mayo Clinic

JAMA Oncology | February 17, 2022 | Volume: 8 | Issue: 4 | Pages: 587

10.1001/jamaoncol.2021.6204 | PMID 35175286 Get It

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study.
Arlt, Weibke, Decoudier, B., Lasolle, Hélène , Quinkler, M., Fragoso, Maria Candida Barisson Villares , Bourdeau, Isabelle , Baudin, Éric , Berruti, Alfredo , Faßnacht, Martin , Libé, Rossella , Lacroix, André , Kaštelan, Darko , Haak, Harm Reinout , Decoudier, B., Bancos, Irina , Canu, Letizia , Puglisi, Soraya , Berchialla, Paola , Beuschlein, Felix , Bertherat, Jérôme , Terzolo, Massimo

Mayo Clinic

Journal of Clinical Oncology | February 16, 2022 | Volume: 40 | Issue: 6_suppl | Pages: 1-1

10.1200/jco.2022.40.6_suppl.001 Get It

1 Background: The ESE-ENSAT guidelines on ACC management suggest adjuvant mitotane for patients at high risk of recurrence. This indication has limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane or observation. The primary endpoint of the study was RFS. Patients who refused randomization were eligible for the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in ADIUVO except for randomization. A total of 91 patients were enrolled in ADIUVO, 45 in the mitotane and 46 in the observation arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with mitotane and observation groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohort was analyzed in parallel to deal with the lower than expected recruitment in ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55-3.32, p = 0.54) and HR for death 2.171 (95%CI, 0.52-12.12, p = 0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed that of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-yr RFS is 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care. Clinical trial information: NCT00777244.
Orbital and Periorbital Dysmorphology in Untreated Pfeiffer Syndrome
Lu, Xiaona, Forte, Antonio Jorge, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Alonso, Nivaldo, Persing, John A., Forte, Antonio J. , Lu, Xiaona , Alonso, Nivaldo , Forte, Antonio Jorge , Lu, Xiaona, Allam, Omar, Park, Kitae Eric, Wilson, Alexander, Alperovich, Michael, Steinbacher, Derek M., Tonello, Cristiano, Persing, John A.

Mayo Clinic

Plastic & Reconstructive Surgery | February 16, 2022 | Volume: 149 | Issue: 4 | Pages: 731e-742e

10.1097/prs.0000000000008928 | PMID 35171849 Get It

Background: Visual impairment secondary to orbital and periorbital dysmorphology is frequent in Pfeiffer syndrome patients. The etiopathogenesis of this aberrancy, however, remains unclear. Methods: Untreated Pfeiffer syndrome patients (n = 31) and normal control subjects (n = 43) were compared. Craniometric and volumetric analyses related to the orbital and periorbital anatomy were performed using Materialise (Leuven, Belgium) software. Results: Overall, orbital cavity volume of Pfeiffer patients is reduced by 28 percent (p < 0.001), compared to normal, starting before 3 months of age (p = 0.004). Globe volume was diminished by 10 percent (p = 0.041) before 3 months of age, yet tended to catch up thereafter. However, the retrobulbar soft-tissue volume remained smaller beyond 1 year of age (17 percent, p = 0.003). Globe volume projection beyond the bony orbit increased in all observed ages (82 percent, p < 0.001). The volumes of sphenoid bone, maxilla, and mandible proportionately were restricted by 24 to 25 percent (p = 0.003 to 0.035) before 3 months of age. The volume of maxilla and mandible gradually approximate normal; however, the sphenoid bone volume in Pfeiffer patients remains less than normal (p = 0.002) into childhood. The anteroposterior length of both the zygoma and the maxilla was reduced by 14 percent (p < 0.001). Anterior positioning of the zygoma is less by 23 percent (p < 0.001) in Pfeiffer patients overall, with anterior positioning of maxilla reduced similarly by 23 percent (p < 0.001). Conclusions: Pfeiffer syndrome patients develop decreased retrobulbar soft-tissue and globe volume, along with a restricted orbital cavity volume in infancy. Significant hypoplasia of the sphenoid bone is associated with more severe central facial (maxilla) retrusion, compared to lateral facial structures (zygoma). CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis?
Hassan, Anhar , Hu, William T. , Josephs, Keith A. , Sorenson, Eric J. , Ahlskog, J. Eric , Mittal, Shivam Om , Hu, William T.

Mayo Clinic

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | February 16, 2022 | Volume: 23 | Issue: 7-8 | Pages: 554-561

10.1080/21678421.2022.2039714 | PMID 35170382 Get It

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
Liang, Minrui , Matteson, Eric L. , Abril, Andy , Distler, Jörg H. W.

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | February 15, 2022 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1759720x221074457 | PMID 35186127 Get It

The major pulmonary complication of rheumatoid arthritis (RA) is interstitial lung disease (ILD), which causes significant morbidity and mortality and influences the natural course of disease. Recent advances in the management of arthritis have improved patient outcomes. However, exceptionally high medical needs still remain for effective therapies for the patients with ILD in RA. Better understanding of the shared and distinct pathophysiology of fibrotic diseases led to the development of novel antifibrotic agents such as nintedanib and pirfenidone. The further stratification analysis of the phase III INBUILD trial demonstrated beneficial effects of nintedanib in RA-ILD with a progressive phenotype by reducing the rate of decline in forced vital capacity (FVC) over 52 weeks by 60%. Pirfenidone is another antifibrotic agent currently under phase II clinical study (TRAIL1) aiming to evaluate its effects for RA-ILD. This review provides an overview of state-of-the-art pathogenesis and the current therapeutic options for RA-ILD, with a focus on antifibrotic strategies.
Artificial Intelligence and Cardiovascular Genetics
Krittanawong, Chayakrit , Johnson, Kipp W. , Choi, Edward , Kaplin, Scott , Venner, Eric , Murugan, Mullai , Glicksberg, Benjamin S. , Amos, Christopher I. , Schatz, Michael C. , Tang, W.H. Wilson , Glicksberg, Benjamin , Amos, Christopher I , Schatz, Michael C , Tang, W H Wilson , Venner, Eric , Wang, Zhen

Mayo Clinic

Life | February 14, 2022 | Volume: 12 | Issue: 2 | Pages: 279

10.3390/life12020279 | PMID 35207566 Get It

Polygenic diseases, which are genetic disorders caused by the combined action of multiple genes, pose unique and significant challenges for the diagnosis and management of affected patients. A major goal of cardiovascular medicine has been to understand how genetic variation leads to the clinical heterogeneity seen in polygenic cardiovascular diseases (CVDs). Recent advances and emerging technologies in artificial intelligence (AI), coupled with the ever-increasing availability of next generation sequencing (NGS) technologies, now provide researchers with unprecedented possibilities for dynamic and complex biological genomic analyses. Combining these technologies may lead to a deeper understanding of heterogeneous polygenic CVDs, better prognostic guidance, and, ultimately, greater personalized medicine. Advances will likely be achieved through increasingly frequent and robust genomic characterization of patients, as well the integration of genomic data with other clinical data, such as cardiac imaging, coronary angiography, and clinical biomarkers. This review discusses the current opportunities and limitations of genomics; provides a brief overview of AI; and identifies the current applications, limitations, and future directions of AI in genomics.
Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors
Upadhyay, Rituraj , Grosshans, David R. , McGovern, Susan L. , McAleer, Mary Frances , Zaky, Wafik , Chintagumpala, Murali , Mahajan, Anita , Yeboa, D.N. , Paulino, Arnold C. , Paulino, Arnold C , Liao, Kai-Ping Eric

Mayo Clinic

Neuro-Oncology | February 11, 2022 | Volume: 24 | Issue: 9 | Pages: 1571-1581

10.1093/neuonc/noac044 | PMID 35157767 Get It

Abstract Background Brainstem toxicity after radiation therapy (RT) is a devastating complication and a particular concern with proton radiation (PBT). We investigated the incidence and clinical correlates of brainstem injury in pediatric brain tumors treated with PBT. Methods All patients &lt;21 years with brain tumors treated with PBT at our institution from 2007–2019, with a brainstem Dmean &gt;30 Gy and/or Dmax &gt;50.4 Gy were included. Symptomatic brainstem injury (SBI) was defined as any new or progressive cranial neuropathy, ataxia, and/or motor weakness with corresponding radiographic abnormality within brainstem. Results A total of 595 patients were reviewed and 468 (medulloblastoma = 200, gliomas = 114, ependymoma = 87, ATRT = 43) met our inclusion criteria. Median age at RT was 6.3 years and median prescribed RT dose was 54Gy [RBE]. Fifteen patients (3.2%) developed SBI, at a median of 4 months after RT. Grades 2, 3, 4, and 5 brainstem injuries were seen in 7, 5, 1, and 2 patients respectively. Asymptomatic radiographic changes were seen in 51 patients (10.9%). SBI was significantly higher in patients with age ≤3 years, female gender, ATRT histology, patients receiving high-dose chemotherapy with stem cell rescue, and those not receiving craniospinal irradiation. Patients with SBI had a significantly higher V50–52. In 2014, our institution started using strict brainstem dose constraints (Dmax ≤57 Gy, Dmean ≤52.4 Gy, and V54≤10%). There was a trend towards decrease in SBI from 4.4% (2007-2013) to 1.5% (2014–2019) (P = .089) without affecting survival. Conclusion Our results suggest a low risk of SBI after PBT for pediatric brain tumors, comparable to photon therapy. A lower risk was seen after adopting strict brainstem dose constraints.